DongKoo Bio&Pharma Co., Ltd. announces an Equity Buyback for KRW 2,000 million worth of its shares.
October 13, 2021 at 09:51 pm EDT
Share
Dongkoo Bio&Pharma Co., Ltd. (KOSDAQ:A006620) announces a share repurchase program. Under the program, the company will repurchase shares for KRW 2,000 million under the contract with NH Investment & Securities Co., Ltd. The purpose of the program is to improve shareholder value and to stabilize stock price. The program will be valid until April 13, 2022.
As of October 13, 2021, the company had 173,504 shares in treasury under the dividend capacity and 0 shares in treasury under other capacities.
Dongkoo Bio&Pharma Co.,Ltd. is a Korea-based company mainly engaged in the production and sale of pharmaceuticals. The major products include antihistamines, topical steroids, therapeutic agents for prostatitis, treatments for benign prostatic hyperplasia, atherosclerotic agents, and antibiotics, among others. The Company is involved in contract manufacturing organization business. It manufactures and sells therapeutic for osteoporosis, antiviral agents, erectile dysfunction treatments, hepatic disease agents; painkillers; gum treatments. In addition, the Company is engaged in the manufacturing and sale of medical devices and cosmetics. The Company distributes its products within the domestic market and to overseas markets, including America and Europe.
DONGKOO BIO & PHARMA CO., LTD. 
